Tony Mok, MD


Is There a Continued Role for First-Generation TKIs in Resectable NSCLC?

January 17th 2022

Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.

The ADAURA Trial: Adjuvant Osimertinib in EGFR+ Resectable NSCLC

January 17th 2022

Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.

Is There a Role for Postoperative Radiotherapy in Stage III NSCLC?

January 12th 2022

A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.

Treatment Strategies for Resectable NSCLC in Asia, With a Focus on Stage IB Disease

January 12th 2022

Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.

Biomarkers for Guiding Treatment in NSCLC: Liquid Biopsy Versus Tissue-Based Testing

January 7th 2022

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

How Has Biomarker Testing Impacted Clinical Practice Across Geographic Regions?

January 4th 2022

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Considerations for Biomarker Testing in NSCLC: Gene Panel Size and Reimbursement

December 22nd 2021

Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.

Regional Recommendations and Approaches to Biomarker Testing in NSCLC

December 22nd 2021

Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.

Dr. Mok Discusses Updated Data With Pembrolizumab in NSCLC

April 25th 2019

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC

August 5th 2016

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.